Search
Diabetes Clinical Trials in Philadelphia, PA
A listing of 30 Diabetes clinical trials in Philadelphia, PA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
25 - 30 of 30
The city of Philadelphia, Pennsylvania, currently has 30 active clinical trials seeking participants for Diabetes research studies.
Featured Trial
Chronic Kidney Disease (CKD) Clinical Study
Recruiting
A clinical study for people that suffer with Chronic Kidney Disease (CKD)
Conditions:
Chronic Kidney Disease (CKD)
Featured Trial
Cardiovascular Disease Clinical Study
Recruiting
A clinical study for people that suffer with Cardiovascular Disease
Conditions:
Cardiovascular Disease
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
Recruiting
The primary objective is to determine the cross-sectional relationship between sleep duration (as measured by 14 days of actigraphy) and glycemic control in an adolescent Type 2 Diabetes (T2DM) cohort (age 12-20y, n=67). A secondary objective is to determine if a loss-framed incentive for achieving sleep goals can increase sleep duration in 15 adolescent patients diagnosed with T2DM with insufficient sleep. Another secondary objective is to test if increasing sleep duration leads to improved gly... Read More
Gender:
ALL
Ages:
Between 12 years and 20 years
Trial Updated:
03/11/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Type 2 Diabetes
Low Dose Fat-Induced Insulin Resistance
Recruiting
The primary goal of this study is to determine the dose of fatty acids that acutely induces mild insulin resistance in healthy volunteers. We hypothesize that a low-dose of fatty acid infusion (Intralipid/heparin) will cause a mild insulin resistance. The dose of fatty acid infusion that reliably causes mild insulin resistance will be selected for use in future studies.
Gender:
ALL
Ages:
Between 18 years and 44 years
Trial Updated:
03/07/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Diabetes Mellitus, Type 2, Insulin Resistance, Insulin Sensitivity
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
Recruiting
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a Strict and permissive threshold. The Strict study arm target range will be 65-120 mg/dL, with time in range goal of 70%. The permissive study arm target range will be 65-140 mg/dL, with target time in range goal of 70%.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Gestational Diabetes, Pregnancy Related
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes
Recruiting
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a strict and permissive threshold. The strict threshold is defined as two abnormal values or more over a one-week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated), whereas the permissive threshold is defined as 50% o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Gestational Diabetes, Pregnancy Related
Phenotyping Genetic Risk for Type 2 Diabetes
Recruiting
This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.
Gender:
ALL
Ages:
Between 10 years and 70 years
Trial Updated:
08/14/2024
Locations: Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania +1 locations
Conditions: Diabetes Mellitus, Type 2, Genetics
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
Recruiting
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/25/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Genetics Disease, Type2 Diabetes, Heart Failure
25 - 30 of 30